BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 34958922)

  • 21. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparison of FibroScan-Aspartate Aminotransferase (FAST) Score and Other Non-invasive Surrogates in Predicting High-Risk Non-alcoholic Steatohepatitis Criteria.
    Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Jang JY; Park SY; Lee HW; Lee CK; Kim SU
    Front Med (Lausanne); 2022; 9():869190. PubMed ID: 35492369
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transient Elastography-Assessed Hepatic Steatosis and Fibrosis Are Associated With Body Composition in the United States.
    Unalp-Arida A; Ruhl CE
    Clin Gastroenterol Hepatol; 2022 Apr; 20(4):e808-e830. PubMed ID: 33549867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies.
    Reddy YK; Marella HK; Jiang Y; Ganguli S; Snell P; Podila PSB; Maliakkal B; Satapathy SK
    J Clin Exp Hepatol; 2020; 10(3):245-254. PubMed ID: 32405181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prevalence and clinical features of non-alcoholic steatohepatitis in a hypertensive population].
    García-Carretero R; Barquero-Pérez O; Mora-Jiménez I; Soguero-Ruiz C; Goya-Esteban R; Rodríguez-Castro C; Ramos-López J
    Hipertens Riesgo Vasc; 2019; 36(3):130-136. PubMed ID: 30655210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High Prevalence of NASH and Advanced Fibrosis in Type 2 Diabetes: A Prospective Study of 330 Outpatients Undergoing Liver Biopsies for Elevated ALT, Using a Low Threshold.
    Castera L; Laouenan C; Vallet-Pichard A; Vidal-Trécan T; Manchon P; Paradis V; Roulot D; Gault N; Boitard C; Terris B; Bihan H; Julla JB; Radu A; Poynard T; Brzustowsky A; Larger E; Czernichow S; Pol S; Bedossa P; Valla D; Gautier JF;
    Diabetes Care; 2023 Jul; 46(7):1354-1362. PubMed ID: 37043830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.
    Harrison SA; Gawrieh S; Roberts K; Lisanti CJ; Schwope RB; Cebe KM; Paradis V; Bedossa P; Aldridge Whitehead JM; Labourdette A; Miette V; Neubauer S; Fournier C; Paredes AH; Alkhouri N
    J Hepatol; 2021 Aug; 75(2):284-291. PubMed ID: 33746083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibroscan-Aspartate Aminotransferase Score Predicts Liver-Related Outcomes, but Not Extrahepatic Events, in a Multicenter Cohort of People With Human Immunodeficiency Virus.
    Sebastiani G; Milic J; Kablawi D; Gioè C; Al Hinai AS; Lebouché B; Tsochatzis E; Finkel J; Ballesteros LR; Ramanakumar AV; Bhagani S; Benmassaoud A; Mazzola G; Cascio A; Guaraldi G
    Clin Infect Dis; 2023 Aug; 77(3):396-404. PubMed ID: 37013396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
    Younossi ZM; Tampi RP; Racila A; Qiu Y; Burns L; Younossi I; Nader F
    Diabetes Care; 2020 Feb; 43(2):283-289. PubMed ID: 31658974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates.
    Garteiser P; Castera L; Coupaye M; Doblas S; Calabrese D; Dioguardi Burgio M; Ledoux S; Bedossa P; Esposito-Farèse M; Msika S; Van Beers BE; Jouët P
    JHEP Rep; 2021 Dec; 3(6):100381. PubMed ID: 34786549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High Prevalence of Advanced Liver Fibrosis Assessed by Transient Elastography Among U.S. Adults With Type 2 Diabetes.
    Ciardullo S; Monti T; Perseghin G
    Diabetes Care; 2021 Feb; 44(2):519-525. PubMed ID: 33303638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
    Kleiner DE; Brunt EM; Wilson LA; Behling C; Guy C; Contos M; Cummings O; Yeh M; Gill R; Chalasani N; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Terrault N; Kowdley K; Loomba R; Belt P; Tonascia J; Lavine JE; Sanyal AJ;
    JAMA Netw Open; 2019 Oct; 2(10):e1912565. PubMed ID: 31584681
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of Steatotic Liver Disease Among US Adults with Rheumatoid Arthritis.
    Vassilopoulos A; Kalligeros M; Vassilopoulos S; Shehadeh F; Benitez G; Kaczynski M; Lazaridou I; Promrat K; Wands JR; Mylonakis E
    Dig Dis Sci; 2024 Mar; 69(3):989-1003. PubMed ID: 38183561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ethnicity and nonalcoholic fatty liver disease.
    Bambha K; Belt P; Abraham M; Wilson LA; Pabst M; Ferrell L; Unalp-Arida A; Bass N;
    Hepatology; 2012 Mar; 55(3):769-80. PubMed ID: 21987488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of liver fibrosis using non-invasive screening tools in individuals with diabetes mellitus and metabolic syndrome.
    Shaji N; Singhai A; Joshi R
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonheavy Alcohol Use Associates With Liver Fibrosis and Nonalcoholic Steatohepatitis in the Framingham Heart Study.
    Rice BA; Naimi TS; Long MT
    Clin Gastroenterol Hepatol; 2023 Oct; 21(11):2854-2863.e2. PubMed ID: 36503167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver disease.
    Barb D; Repetto EM; Stokes ME; Shankar SS; Cusi K
    Obesity (Silver Spring); 2021 Nov; 29(11):1950-1960. PubMed ID: 34553836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonalcoholic Steatohepatitis: A Review.
    Sheka AC; Adeyi O; Thompson J; Hameed B; Crawford PA; Ikramuddin S
    JAMA; 2020 Mar; 323(12):1175-1183. PubMed ID: 32207804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.
    Leite NC; Villela-Nogueira CA; Pannain VL; Bottino AC; Rezende GF; Cardoso CR; Salles GF
    Liver Int; 2011 May; 31(5):700-6. PubMed ID: 21457442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The epidemiology of non-alcoholic steatohepatitis (NASH) in the United States between 2010-2020: a population-based study.
    Hamid O; Eltelbany A; Mohammed A; Alsabbagh Alchirazi K; Trakroo S; Asaad I
    Ann Hepatol; 2022; 27(5):100727. PubMed ID: 35700934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.